UV Therapy LED Spectral Optimization for Erythema Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional ultraviolet therapy apparatus using LEDs as light sources often experience lower therapeutic effects and increased side effects, such as erythema, compared to those using excimer lamps, due to differences in emission spectra and intensity ratios.
Innovation Solution
The ultraviolet therapy apparatus employs LEDs with specific emission spectrum characteristics, including a ratio of integral intensities in certain wavelength ranges, to achieve therapeutic effects comparable to or better than excimer lamps while minimizing side effects, by configuring the LEDs to emit less intense light in the 250 nm to 298 nm range and more intense light in the 308 nm to 313 nm range, thereby optimizing the balance between therapeutic efficacy and side effect risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Weight of stationary object
If conventional LEDs with peak wavelength of 308 nm are used as light source, then the apparatus size and weight are reduced compared to excimer lamps, but therapeutic effects are lowered and side effects (erythema) increase
Solution Approach 1:
The patent applies parameter changes by precisely controlling the emission spectrum characteristics of LEDs, specifically setting the ratio of integral intensity in 250-298 nm range to total integral intensity (250-400 nm) at ≤0.088, and the ratio of integral intensity in 308-313 nm range to 250-298 nm range at ≥5.2. This spectral parameter optimization reduces harmful short-wavelength UV while maintaining therapeutic mid-wave UV, resolving the contradiction between apparatus compactness and side effect reduction.
Solution Approach 2:
The patent employs multiple LED types with different emission characteristics in combination, dynamically adjusting the overall emission spectrum through selective arrangement of LEDs. This allows optimization of both therapeutic effect and side effect reduction while maintaining the compact LED-based apparatus structure.
2Weight of stationary object
If conventional LEDs with peak wavelength of 308 nm are used as light source, then the apparatus size and weight are reduced compared to excimer lamps, but therapeutic effects are lowered
Solution Approach 1:
The patent optimizes therapeutic effect by controlling spectral parameters: limiting integral intensity ratio in 250-298 nm range to ≤0.088 of total (250-400 nm) and ensuring integral intensity ratio in 308-313 nm range to 250-298 nm range is ≥5.2. This parameter control ensures sufficient mid-wave UV for therapy while minimizing harmful short-wave UV, achieving both compact design and effective treatment.
Solution Approach 2:
The patent uses dynamic spectral composition by combining multiple LED types with different emission characteristics, allowing optimization of both therapeutic efficacy and apparatus compactness through selective arrangement of LEDs with specific spectral properties.
3Object-affected harmful factors
If excimer lamps are used as light source, then therapeutic effects are achieved with good side effect profile, but the apparatus becomes larger and heavier
Solution Approach 1:
The patent extracts and eliminates the harmful short-wavelength component (250-298 nm) from the UV spectrum while retaining the therapeutic mid-wave component (308-313 nm). By using LEDs with controlled emission spectra that inherently limit short-wavelength output, the patent achieves excimer lamp-level side effect profiles without the bulk and weight of lamp-based systems.
Solution Approach 2:
The patent changes the spectral emission parameters by selecting and arranging LEDs to achieve specific integral intensity ratios: ≤0.088 for 250-298 nm range and ≥5.2 for 308-313 nm to 250-298 nm ratio. This parameter control enables compact LED-based apparatus to match or exceed excimer lamp performance in side effect reduction.
4Productivity
If excimer lamps are used as light source, then therapeutic effects are achieved with good side effect profile, but the apparatus becomes larger and heavier
Solution Approach 1:
The patent optimizes both therapeutic effect and apparatus weight by controlling LED emission spectrum parameters: integral intensity in 250-298 nm range ≤0.088 of total (250-400 nm) and integral intensity in 308-313 nm range to 250-298 nm range ratio ≥5.2. This ensures sufficient mid-wave UV for therapy while maintaining compact LED-based design.
Solution Approach 2:
The patent extracts the harmful short-wavelength component while preserving therapeutic mid-wave UV output. By using LEDs with controlled spectra that naturally limit 250-298 nm emission, the patent achieves effective therapy with compact apparatus, eliminating the weight penalty of excimer lamp systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized LED configuration in the ultraviolet therapy apparatus achieves similar or improved therapeutic effects with reduced side effects, as demonstrated by increased minimal erythema dose and improved treatment efficiency, while also reducing the size and weight of the apparatus and enhancing energy efficiency.
Implementation Method 1
a light source unit that emits ultraviolet light, the light source unit comprising at least one LED
Implementation Method 2
an ultraviolet therapy apparatus that uses LEDs as the light source
Data Source
AI summary
An ultraviolet therapy apparatus is provided and includes a light source unit that emits ultraviolet light, the light source unit comprising at least one LED, the LED being configured to, in a case in which an integral intensity of an emission spectrum in a wavelength range of 250 nm to 400 nm is 1, have a ratio of an integral intensity in wavelengths of 250 nm to 298 nm to an integral intensity in the wavelength range is less than or equal to 0.088, and emit an emission spectrum such that a ratio of an integral intensity of wavelengths of 308 nm to 313 nm to an integral intensity of wavelengths of 250 nm to 298 nm is greater than or equal to 5.2.